Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of
oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic
benefit of oritavancin administered as a single 1200 mg IV dose.